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1. Introduction
What is the reason that mitochondrion is so attractive target for pharmacotherapy? The
problem raised is a bit complex. Although the appearance of mitochondria in animal cells
started more than one million years ago, when the proteobacteria (in particular, Rickettsiales
or close relatives) entered and practiced coexistence inside eukaryotic cells via endocymbiosis,
But the biological science started to pay attention on mitochondria in the middle of 19th century,
the time that mitochondria were discovered in tissue section of liver and flight muscle. The
earliest definition of this organelle in cells was written by Richard Altmann on 1890, when he
named them as ‘‘bioblasts’’ and hypothesized that they were ‘‘elementary organisms’’ living
inside cells with ‘‘vital functions’’ [1]. After 1890, the progress in understanding the structure
and function of mitochondria was quite steady, but we can single out major milestones in every
decade. In the 1950s, investigators analyzed mitochondria by electron microscopy and
characterized that they are the sites of respiration, Oxidative Phosphorylation (OXPHOS) and
fatty acid oxidation. In the 1960s, investigators found out mitochondrial DNA (mtDNA) and
described chemiosmotic theory. In the 1980s, the first consummate sequence of mammalian
mtDNA and the first molecular identification of a cause of mitochondrial diseases were
reported. A great incrementation in interest on mitochondria occurred in 1996, when research‐
ers demonstrated that the organelles are associated with programming cell death or apoptosis
[2]. After this manifestation, mitochondrial study commenced growing as a biomedical field.
Owing to the unique structure and function of mitochondria, several clinically used drugs can
improve or damage their bioenergetics. These drugs can act via the regulation of: (a) perme‐
ability transition pores (PTPs), (b) fatty acid uptake or oxidation, (c) the electron transport
chain (ETC), (d) cardiolipin (CL) content (e) ion channels and transporters, (f) Adenosine
triphosphate (ase) (ATPase) and (g) mtDNA and protein synthesis [3]. Mitochondria are sub-
cellular organelles that play pivotal roles essential for energy (ATP) production, metabolism,
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and homeostasis. In addition, mitochondria orchestrate some survival and cell death signaling.
The reason why the mitochondria is considered as a potential drug target for the treatment of
hyperproliferative and metabolic disorders. Unsimilarities in the reduction/oxidation condi‐
tion of tumor versus non-tumor cells may be beneficial to get selective cytotoxic and anti-
colonygenic effect on tumor cell populations. It was shown that pro-oxidant drugs, including
Elesclomol and Trisenox have therapeutic benefits in the treatment of cancer. Findings
obtained with Bz-423 in mouse demonstrate the potential for mitochondria-targeted drugs to
control disorders of immune function. Investigation associating an elevated oxidant state with
mitochondrial damage, aging dictates, and degenerative disease the need for a better under‐
standing of how and when pharmacological manipulation of mitochondrial function prepares
most therapeutic benefit [4].
Mitochondria carry out vital biochemical functions essential for cells such as homeostasis
calcium, cell death and survival, in addition to ATP production. They represent a convergence
point for death signals triggered by both intracellular and extracellular cues. Not surprisingly
it's incoherent, therefore, mitochondria additionally offer targets for xenobiotics to exert either
detrimental or therapeutic effects on cell survival and function. Efforts to harness mitochon‐
drial targets for therapeutic benefit have focused largely on cancer, although treatments for
ischemia, metabolic diseases and neurodegenerative diseases also are being explored. This
chapter will describe current thinking and recent advances in the discovery of small molecule
drugs acting on targets in the mitochondrion [5].
2. Why we choose mitochondria for drug targeting
The mitochondrion is as a respiratory organelle exists in almost all eukaryotic nucleated cells.
Its unique structure is consisted of four distinct sub-structures with different specific functions:
the mitochondrial matrix, the inner mitochondrial membrane (IMM), the outer mitochondrial
membrane (OMM) and the intermembrane space (IMS). The structure of the inner mitochon‐
drial membrane (IMM), is extensively folded and compartmentalized. The numerous invagi‐
nations of the membrane are called cristae, which house the 4 complexes of the mitochondrial
respiratory chain and ATP synthase, controlling the vital levels of cellular bioenergetics. This
primary function of the mitochondrion is responsible for supplying cellular energy, the reason
why we call it power plant of the cell.’’ However, it is not the only important function of
mitochondria in the cell [6]. Adenosine triphosphate (ATP) production through the oxidative
phosphorylation (OXPHOS) process requires a continuous flow of electrons. As such, mito‐
chondria are the major so are the major source of reactive oxygen species (ROS, i.e. superoxide
and H2O2), generated as byproducts of the ETC. ROS reflect the level of cellular oxidative stress,
causing severe damage to macromolecules when overproduced. Consequently, according to
the Harman’s oxidative stress theory, they have been linked to aging, age-related pathologies,
and death. However, when produced in a controlled amount, ROS may also play important
signaling roles in various redox-dependent processes, including apoptosis, cell proliferation
and hypoxia. Furthermore, mitochondria are active players in cellular calcium homeostasis.
Mitochondrial Ca2+ accumulation regulates functions as diverse as aerobic metabolism and
induction of cell death. Finally, mutations in mitochondrial DNA (mtDNA) are responsible
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for many mitochondrial metabolic disorders, and are thought to contribute to aging by
promoting apoptosis. Thus, because of their pivotal role in regulating cell life and death,
mitochondria represent an attractive target for mitochondrial gene therapy as well as drugs
treating either degenerative or hyper proliferative diseases (figure 1) [7].
Some aspects of mitochondrial biogenesis and some important roles of mitochondria in cell function are illustrated.
One major function of mitochondria is the production of energy (ATP) via aerobic metabolism of glucose which is
called oxidative phosphorylation. Initially, glucose is metabolized to pyruvate through cytosolic glycolysis (anaerobic
metabolism). Voltage-dependent anion channels (VDACs), also called porin channels, allow low molecular weight
molecules to enter the mitochondrial inter membrane space. Following the activation of AMPK (AMP-dependent kin‐
ase), cell responds to the decreased ATP/ADP ratio in the cytosol through alterations in AMP, and affects several tar‐
gets. Mitochondrial mtDNA encodes 37 genes that are involved in the synthesis of the respiratory chain and the ATP
production. Additional proteins are imported through TIM (transporter inner membrane) and TOM (transporter outer
membrane), translocases of the inner and outer membranes that transport nuclear-encoded proteins into mitochondria.
The adenine nucleotide translocase (ANT) enables the mitochondrion to import ADP and export ATP. Mitochondria
also contribute to calcium homeostasis by taking up calcium into the mitochondrial matrix through the calcium uni‐
porter in response to changes in cytosolic calcium. In addition, mitochondria play a crucial role in cell death such as
apoptosis and necrosis. When apoptotic signals occur, the outer membrane becomes compromised and the mitochond‐
rion experiences mitochondrial outer membrane permeabilization (MOMP), leading to the release of cytochrome c (cyt
c) and many other pro-apoptotic proteins from the intermembrane space into the cytosol where they activate apoptotic
cell death [6].
Figure 1. Mitochondrial biogenesis and function.
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3. Mitochondrial diseases
Mitochondrial dysfunction triggers the cell death signaling cascade and results in organ failure
and disease. Therapeutic intervention at the mitochondrial level can be envisioned for general
cell-degenerative as well as hyper proliferative diseases, i.e. cancers. Hyper proliferative cells
are sensitive to pro-oxidant that induced apoptosis through increasing of their oxidative stress
level. The redox status of many tumors is significantly changed compared with normal tissue,
and pro-oxidant drugs can use this difference for treatment of proliferative disorder. Con‐
versely, degenerative and aging diseases are associated with an elevated oxidant state that
may associate mitochondrial damage. In these cases, antioxidants targeting mitochondria are
hoped to exert a justifying effect. Several studies are found in this category, all sharing the
common features of disturbances of mitochondrial ROS, ATP or Ca2+ metabolism. They contain
cardiovascular diseases (for example atherosclerosis, ischemia/reperfusion injury, heart
failure, stroke); aging and neurodegenerative diseases (for example Alzheimer’s disease (AD),
Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and
Friedreich’s ataxia (FRDA)); chronic autoimmune inflammatory diseases (for example
rheumatoid arthritis (RA)) ; metabolic diseases(for example diabetes and obesity) ; as well as
ionizing radiation injury (Table 1) [6].
Cardiovascular
diseases
Neurodegenerative
diseases
Chronic autoimmune
inflammatory diseases
Metabolic
diseases
Cancer
Atherosclerosis Alzheimer’s disease
(AD)
rheumatoid arthritis (RA) diabetes Hepatocellular
carcinoma
Ischemia/reperfusion
injury
Parkinson’s disease
(PD)
obesity Adenocarcinoma
Heart failure Huntington’s
disease (HD)
Breast cancer
Stroke amyotrophic lateral
sclerosis (ALS)
Prostate cancer
Congestive heart failure Friedreich’s ataxia
(FRDA)
Table 1. The table above contains some disease that role of mitochondria in these diseases has been demonstrated.
Which are divided into five categories.
4. Strategies to target mitochondria
Small molecule drugs or biologics can act on mitochondria through various pathways. Many
of these mechanisms will be argued in more detail in the below sections, and a detailed
discussion would immensely encroach the purpose of this chapter, but attractive current
approaches include OXPHOS uncoupling, mitochondrial Ca2+ modulation, ETC inhibition and
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control of oxidative stress through increase or decrease of mitochondrial ROS accumulation.
The inhibition of the ETC can happen through direct inhibition of a protein subunit of one or
more of the enzyme complexes or via reception of electrons current across the ETC instead of
the natural receiver cytochrome c or ubiquinone. In the Oxidative Phosphorylation (OXPHOS)
uncoupling occurrence, protons are shifted from the mitochondrial matrix to the intermem‐
brane space (IMS) and do not avert across the F1F0-ATPase and back to the matrix, but instead
migrate directly across the inner mitochondrial membrane (IMM). This bypass results in lack
of ATP formation but heat production. Typical instances for agents that elevate OXPHOS
uncoupling are weak bases and weak acids, which can be protonated in the IMS and carry
protons across the IMM. Interestingly, compounds affecting the activity of inner membrane
uncoupling proteins (UCPs) can inhibit cell death. An important occurrence starting the
apoptotic cascade is the mitochondrial membrane permeabilization (MMP), which begins the
collapse of the mitochondrial potential (∆Ψ), the release of cyt c and other protease and
nuclease activators. The inhibition of this process can be attained with inhibitors of the
mitochondrial permeability transition pore (mPTP) complex, openers of the mitochondrial
ATP-regulated (mitoKATP) or inhibitors of the mitochondrial Na+-Ca2+ exchange or
Ca2+activated (mitoKCa) potassium channels. Modulation of mitochondrial Ca2+ can also be
envisioned by interference with mitochondria-specific Ca2+ transporters. Additional strategies
for drug-induced perturbation of mitochondrial biochemistry include the inhibition of the cyt
c-catalyzed peroxidation of the mitochondria-specific phospholipid CL, and the targeting of
other specific mitochondrial proteins via inhibition of kinases, F1F0-ATPase, enzymes of the
Krebs cycle, or members of the anti-apoptotic Bcl-2 family. It has been known for a while that
inhibition of the oxidative cellular damage through a decrease of mitochondrial ROS accu‐
mulation can be attained by the delivery of antioxidants acting as radical and/or electron
scavengers. Many compounds are able to inhibit the β-oxidation of unsaturated fatty acids,
causing cellular accumulation of fat. Alternatively, anti-apoptotic agents could be designed
via inhibition of the cyt c-catalyzed peroxidation of CL. Finally, the mitochondrial biochem‐
istry is also severely derailed by mtDNA binding/oxidation or inhibition of mtDNA synthesis,
or modulation of mitochondrial fission/fusion. Chemical agents that bind to mtDNA often
result in inhibition of DNA synthesis. If adequate selectivity in the binding process can be
acceded, this mechanism f action may display an attractive strategy to block the expression of
mutated mtDNA accountable for genetic mitochondrial disarrays. Lately, compounds that
modulate mitochondrial fission/fusion have been suggested as a valuable replacement in
treatment of neurodegenerative diseases (figure 2) [6]. While the OMM is relatively permeable
due to the abundance of the VDAC protein, the IMM is extremely impermeable and acts as a
stiff barrier to the passive propagation of all types of molecules. It is also wealthy in the unusual
phospholipid cardiolipin (CL), and keeps a strong negative internal potential of −180 mV
needed for the ETC function. A widely used strategy for targeting mitochondria takes benefit
of this considerable biophysical membrane nature, since cationic molecules are attracted to
and accumulate preferentially within the negatively charged mitochondrial matrix. Another
strategy is based on the access of an agent to mitochondrial membrane components, particu‐
larly to the phospholipid cardiolipin CL which is particularly found in the IMM. Moreover the
former more specific properties, adequate lipophilicity is also needed to achieve an adequate
enrichment in mitochondrial compartments. A rising approach to the selective delivery of
bioactive cargo molecule into mitochondria uses a carrier of short peptide sequences with
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specific physicochemical properties. For example, Horton et al. newly reported such mito‐
chondria-penetrating peptides with changing cationic and hydrophobic residues. Other
variants have been based on an oligomeric carbohydrate scaffold, always attaching key
guanidinium moieties due to their delocalized cationic form. Finally, the tethering of active
molecules to mitochondrial targeting sequences (MTSs) has also been successively utilized.
Mitochondrial targeting sequences (MTSs) are peptides applied by cells for the delivery of
nuclear-encoded mitochondrial proteins, comprising structural motifs recognized by the
mitochondrial import machinery. Another class of mitochondrial delivery vectors, appropriate
for the import of impermeable or big molecules, is the vesicle-based transporter system. The
targeted agent is encapsulated in a cationic liposome, which undergoes cellular internalization
and subsequent fusion with the OMM. In summary, by the utilization of a wide range of
various delivery systems, the targeting of mitochondria for therapeutic advantages can be
employed to enrich both pro-oxidants as well as antioxidants in mitochondrial compartments.
Antioxidants are of preliminary interest for their antiaging properties, with some of the main
applications centered neurodegenerative and cardioprotection diseases, while cytotoxic and
pro-oxidant agents are under research for cancer therapy [6].
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Figure 2. Pharmacological targeting of mitochondria of possible sites of drug action.
4.1. Targeting the mitochondrial electron transport chain
Mitochondria are unusual organelles. They act as the power plants of the cell, are surrounded
by two membranes, and have their own genome. The mitochondrion consists a matrix
encircled by two membranes, the MOM and the MIM. The MIM comprises several invagina‐
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tions called cristae and is very impermeable to ions and small molecules, which need specific
transport proteins to exit or enter the mitochondrial matrix. Under aerobic statuses, the
proteins of the ETC, placed in the MIM, reduce oxygen to water through a series of steps along
the electron transport chain that use NADH and FADH2 derived from the glycolysis and
tricarboxylic acid cycle. These reductions effectively efflux protons (H+) through the MIM such
that they accumulate in the IMS creating a pH gradient across the MIM that contribute to an
overall electrochemical gradient (DC). This gradient as a source of energy to drive the synthesis
of ATP from ADP and phosphate is applied by the mitochondrial F1F0-ATPase. This succes‐
sion of chemical stages is collectively known as OXPHOS.
Small amounts of ROS are generated as a result of incomplete oxygen reduction in during
normal OXPHOS. ROS comprise superoxide, the result of partial oxygen reduction, hydroxyl
radicals and the subsequently formed hydrogen peroxide, each of which displays different
chemistry. A high NADH: NAD+ ratio (as may arise owing to high rates of glycolysis) can
increase ROS production, as does state 4 respiration in which electron transport occurs in the
loss of ATP synthesis, for instance, when ADP levels are low [8]. Inhibitors of the ETC and of
the F1F0- ATPase can also enhance mitochondrial ROS production. ROS act as secondary
messengers with important signaling roles, but in addition ROS contribute to oxidative
damage of cellular macromolecules. It is also remarkable that the production of ROS has been
recognized as a widespread mechanism for the bactericidal effect of many widely used
antibiotics including drugs targeting DNA, the cell wall and protein synthesis [9]. Thus, ROS
perform both a destructive role and necessary role in cells. Inhibitors of the electron transport
chain are useful tools for furthering our understanding of this essential bioenergetics process
[10]. Inhibitors of complex I (NADH ubiquinone oxidoreductase) include the photochemical
Annonaceousacet ogenins that have been attributed with antimicrobial and anticancer
properties and rotenone used as a rodenticide. The widely used diabetes drug metformin
inhibits complex I and has been shown to induce AMP-activated protein kinase-dependent
and p53 increase in glycolysis to countervail for modulation of the respiratory chain, which
effectively increases glucose utilization. Succinate–ubiquinone oxidoreductase (Complex II) is
one proposed target of redox-silent vitamin E analogs such as α-tocopheryl succinate.
Cytochrome c oxidoreductase (complex III) is inhibited by the natural product myxothiazole
and by antimycin A (the active constituent of the piscicide Fintrol).Cytochrome c oxidase
(complex IV) is a target of cyanide. Complex I and complex III are the main sources of
mitochondria derived ROS in vitro, although the synthesis of superoxide by complex III is
considered to be more physiologically related. The electron transport chain provides the H+
gradient that is necessary for the mitochondrial F1F0- ATPase to function. The related
macrolide apoptolidin and Oligomycin, a natural product that blocks the proton channel are
both inhibitors of the F1F0-ATPase.Apoptolidins display remarkably selective cytotoxicity
toward a subset of tumor cell lines in vitro, suggesting that inhibition of the ATPase is not
exactly cytotoxic. Other compounds reported to bind to the F1F0-ATPase include aurovertin,
resveratrol, PK1119, Bz-423, and diindolyl methane (DIM) [11]. The benzodiazepine derivative
Bz-423 was identified as a lead for the treatment of autoimmune diseases.Bz-423 reduces
disease in murine models of lupus, psoriasis, and arthritis and has cytotoxic and anti-prolif‐
erative effects on tumor cells in vitro. Bz-423 is an uncompetitive inhibitor of the F1F0-ATPase,
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deceleration the ATPase without causing a significant drop in cellular ATP levels. The
therapeutic effects of this compound are moderated by the induction of superoxide O2-.
Resveratrol, a constituent of grape skins, increases longevity in rodents and has been attributed
with beneficial effects against inflammation, heart disease, and cancer. Notwithstanding the
existence of a crystal structure of resveratrol bound to the F1F0-ATPase, this protein is one of
several reported targets for resveratrol and related compounds, including the protein deace‐
tylase, sirtuin [5].
The ETC and the F1F0-ATPase proteins can be decoupled by uncoupling proteins that promote
the leakage of protons back through the MIM. The resulting drop in membrane potential
reduces ROS production and represents a natural protective mechanism against inhibition of
respiration. This is a natural process that results in thermogenesis. F1F0-ATPase inhibitors,
without affecting ATP synthesis, specifically block ATP hydrolysis have been described: such
compounds should be effective under ischemic conditions when the ATPase can operate in
the reverse of its normal direction leading to a catastrophic drop in ATP levels that causes cell
death [12]. This premise has not been tested clinically. Mammalian and bacterial ATP synthases
exhibit substantial differences in structure and intracellular location presenting the opportu‐
nity for species selective ATP synthase modulation [5]. The mycobacterial ATP synthase
inhibitor, R207910, is currently in Phase III trials for the treatment of tuberculosis [13].
4.2. Targeting transporters and channels in mitochondria
It is well recognized that the totality of the mitochondrial membrane is crucial for mitochon‐
drial function. Not only are the inner and outer membranes targeted by drugs, but, in addition,
many of the ion channels, proteins, and transporters embedded within the lipid membrane
are also targeted. Among the main drug targets are: 1) lipophilic cations targeting the IMM
(e.g., rhodamine-123) 2)cardiolipin(CL) (e.g., 10-N-alkyl-arcine orange), 3) carnitine palmi‐
toyltransferase- 1 (CPT-1) inhibitors (e.g., oxfenicine, perhexiline, and etomoxir), 4) Na+/ Ca+2
exchanger regulators, 5) B-cell lymphoma 2 (Bcl-2) protein inhibitors (e.g., gossypol) 6) IMM
potassium channel regulators (e.g., glibencamide and diazoxide), and 7) MPT pore complex
regulators (e.g., CsA).We can activate permeabilization of the mitochondrial membrane or can
protect membrane integrity. Among the best mitochondrial protein targets for many drugs are
a group of proteins that form the PTP complex across the OMM and IMM. This complex is
responsible for mitochondrial permeability transition and plays a crucial role in both survival
and death signaling pathways. Depending on the pharmacological strategy, MPT pore
activation stimulates apoptosis and prevents the differentiation of many tumor cells. Strategies
to induce this effect typically involve direct action against the MPT pore protein complex or
indirect action via depleting endogenous inhibitors of MPT pore or increasing ROS and
calcium ions in the cytoplasm. Various MPT pore complex inhibitors, in anticancer therapeutic
approaches, are used, including: 1) hexokinase modulators such as glucose-6-phosphate and
glucose 2)creatine kinase modulators such as cyclocreatine and creatine; 3) cyclophilin D
(CypD) -affecting drugs such as sanglipherin A and CsA; 4) voltage dependent ion channel
modulators such as arsenic trioxide; 5) benzodiazepine receptor modulators such as Ro-54846
and PK11195; and 6) adeninenucleotide translocase modulators such as CD437, PENAO (4-(N
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(Spenicillaminylacetyl) amino) phenylarsonous acid), lonidamide, betulinic acid, clotrane, and
bongkrekic acid, GSAO (4-[N-[S-glutathionylacetylamino] phenylarsenoxide)[14], GSAO and
PENAO are tumor-metabolism inhibitors that target ANT of the inner-mitochondrial mem‐
brane. Both the compounds are currently being appraised in trials in patients with solid
tumors. The trivalent arsenical moiety reacts with the two matrix-facing cysteine residues of
ANT, inactivating the transporter. This leads to tumor-supporting cells and death and
proliferation arrest of tumor cells [14].Above-mentioned drugs grouping although useful
appears to be synthetic, and surely will be modified. According to some authors MPT pore
may consist of quite different proteins. Recent investigation on MPT pore molecular identity
has to redefine a new context on described interaction.CL, a negatively charged phospholipid,
is almost exclusively localized in the mitochondrial inner membrane. CL maintains architec‐
ture and membrane potential. A loss of CL content has been associated with mitochondrial
damage in multiple tissues in a variety of pathological conditions, including aging, heart
failure, and ischemia. It was reported that preadministration of NAO (10-N-alkyl-arcine
orange), that is a dye associated specifically with CL, decreased the release of cytochrome c, a
component of the ETC in mitochondria, released in response to pro-apoptotic stimuli [15].
Another drug target example is CPT-1, an enzyme located in the OMM and responsible for
the transport of long-chain fatty acids across the membrane by binding them to carnitine.
Perhexiline and etomoxir (antianginal agents) act by inhibiting CPT-1 and protect heart from
fatty acid-induced ischemic injury [16].
In contrast to the MIM, the mitochondrial outer membrane is more permeable to small
molecules so that the IMS resembles cytosol in its small molecule composition. In addition,
however, the IMS sequesters proteins such as apoptosis inducing factor (AIF), smac/ Diablo
(second mitochondria derived activator of caspases), and cyt c that when released into the
cytosol activate caspases and induce apoptosis. One process for the release of these death
inducing protein factors involves swelling of the mitochondrion so that the outer membrane
ruptures producing MPT. These events are mediated by the MPT, a channel that comprises
multiple proteins including the VDAC located in the MOM, ANT located in the MIM, as well
as the peripheral benzodiazepine receptor (PBR), CypD, hexokinase, and possibly also
Bax.andBcl-2 Inhibitors of the MPTP have been reviewed elsewhere as have inhibitors of Bcl-
family proteins. High affinity ligands of the PBR have been associated with immunothera‐
peutic and anticancer properties. The relationship of these effects to physiological functions
of the PBR requires more study. Newly, VDAC ligands identified in cell-based screens were
shown to be cytotoxic toward cells bearing oncogenic Ras protein [4].
4.2.1. Targeting mitochondrial Adenine nucleotide translocator (ANT)
Adenine nucleotide transporter interacts with Voltage dependent anion channel (VDAC) and
cyclophilin D and other proteins to make the mitochondrial permeability transition pore
(mPTP) at locations where IM contacts OM [17]. Adenine nucleotide transporter (ANT), the
key IM protein of mPTP, exchanges ATP and ADP. ANT can form mitochondrial permeability
transition pores (mPTP) which induces other membrane leakiness of mitochondria and
subsequent swelling of matrix. This event happens following the surface area of the IM (with
its folded cristae) exceeds that of the OM. Quite in contrast, the conformation of ANT is
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modulated by ANT ligands [18] and sensitive interaction of cyclosporine A with cyclophilin
D, indirectly blocks VDAC activity. When reconstructed into planar lipid bilayers or into
liposomes or into planar lipid bilayers, ANT can form nonspecific channels in response to
proapoptotic agents such as the HIV-1 viral protein R (Vpr), Ca2+, lonidamine and atractyloside.
Moreover, ANT channel formation is inhibited by Bcl-2 and enhanced by Bax. However, mouse
knockout studies led to the conclusion that ANT would not (always) be required for apoptotic
MPT. Recent evidence suggests that some ANT isoforms (ANT1, ANT3) are apoptogenic while
others are not (ANT2)[19]. In 2005, a fourth ANT isoform (ANT4) has been identified in mouse
and man by means of two independent experimental approaches. ANT2, which are over
expressed in cancer cells, help to stabilize mitochondrial membranes and survival cell. Indeed,
it was suggested that in cancer cells, small interfering RNA (siRNA) that down regulate ANT2
may constitute a valid strategy for the selective induction of tumor cell apoptosis [20].
4.2.2. Targeting mitochondrial cyclophilin D
CypD is a nuclear-encoded mitochondrial isoform of cyclophilin, with a molecular mass of 18
kDa. It enters mitochondria using a targeting sequence that is cleaved following translocation
into the matrix. At present, extensive data have been obtained in favor of Cyclophilin D as an
essential component and key regulator of MPT pore using various pharmacological inhibitors
and genetic manipulations. The first evidence for the involvement of Cyclophilin D in MPT
pore formation came from studies showing an inhibitory effect of CsA, extensively used in
tissue and organ transplantation, as an immunosuppressant, on pore opening. Other docu‐
ment for the essential role of Cyp D in MPT pore formation has been reported by several
independent groups in reports with Cyp D knockout mice in which mitochondria isolated
from these animals displayed a low sensitivity to Ca2+and, as a result, a delayed MPT pore
opening. The inhibitory effect of CsA and its analogs involves interaction with Cyp D that
reduces sensitivity of pore opening to Ca2+. Cyp D favors MPT pore opening by facilitating the
Ca2+triggered conformational change. Most probable, interaction of CypD and Ca2+, P and the
pore is a multifaceted process that also includes enhancement of susceptibility of the MPT pore
proteins to oxidative stress [21].
Several studies have shown that Cyp D is up-regulated in many human tumors and can
function as an apoptosis repressor. Growing number of evidence demonstrated that the anti-
apoptotic regulation of Cyp D might be associated with the stabilization of hexokinase II
binding to mitochondria. Inactivation of CypD with cyclosporine A or knock- down of the
expression using siRNA was shown to release hexokinase II from mitochondria. Because Cyp
D is a mitochondrial matrix protein, an intermediate in the IMM between the OMM and matrix
is necessary for its modulation of hexokinase II binding to VDAC. ANT in the IMM could play
this intermediation role.However, study showed the opposing pro-apoptotic role of Cyclo‐
philin D in apoptosis. They demonstrated that hexokinase II detachment-triggering apoptosis
might be associated with a disruption of the interaction of Cyp D with ANT. Furthermore,
inhibition of CyP-D was shown to prevent the onset of the MPT pore [22].
The MPT pore, a critical mediator of cell death, has appeared as a serious therapeutic target
for limiting acute ischemia reperfusion injury. The genetic amputation and pharmacological
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inhibition of mitochondrial Cyp D, a key mediator of apoptosis signaling, has emerged as an
important therapeutic target for minimizing acute hypoxic/ischemic injury. The genetic
ablation and biological inhibition of mitochondrial cyclophilin-D (CypD), a regulatory
component of the mitochondrial permeability transition pore (mPTP), has been reported to
decrease myocardial infarction progression in in vivo studies. However, it is note worthy that
CypD-deficient hearts are still susceptible to mPTP opening and cell death signaling occurred
through mechanisms which are not dependent on CypD. Very recently, cyclosporin-A (CsA),
an immunosuppressive therapeutic agent and biological inhibitor of CypD has been shown to
reduce myocardial infarction progression and improve left ventricular function in ST-elevated
MI patients undergoing primary percutaneous coronary surgery, given at reperfusion [23].
Animals lacking CypD display increased resistance to ischemic insults,  muscular dystro‐
phies, multiple sclerosis (MS), ALS, and AD, and the CypD inhibitor CsA and its analogs
have  displayed  neuroprotective  effects  in  several  animal  models  of  acute  neurological
damage and chronic neurodegenerative disease. Preserving the integrity of mitochondrial
membranes through inhibition of mPT has been put forward as the central mechanism for
the neuroprotective and cardioprotective effects of CsA, even though the drug has several
pharmacological targets. It has also been suggested that CypD is downregulated in neurons
during development, which would decrease the sensitivity of the MPT pore to calcium, and
prohibit  the  use  of  CypD as  a  pharmacological  target  in  disorders  of  the  adult  central
nervous system (CNS) [24].
4.2.3. Targeting mitochondrial peripheral benzodiazepine receptor (PBR)
The elaborate structure of mitochondria is important for the normal performance of the
organelle and as a potential therapeutic target. Two specialized membranes embed each
mitochondrion, dividing the organelle into an arrow IMS restricted by the OMM and the inner
IMM. The OMM comprises many channels formed by the protein porin that makes the
membrane relatively permeable. One of the membrane proteins is the peripheral benzodiaze‐
pine receptor (PBR). PBR is a small evolutionarily conserved protein involved in steroid
synthesis and cholesterol transport; it is also a regulator of apoptosis. The PBR is also involved
in OMM permeabilization by interaction with the pro-apoptotic Bcl family of proteins.
However, OMM permeability maybe independent of MPT pore opening because blocking PBR
with 4’-chlorodiazepam (CDZ) prevents against ischemia-induced cytochrome c release
independent of damage to the IMM;4’-chlorodiazepam (CDZ)also reduces ischemia-induced
arrhythmias. PBR is found in close association with the VDAC and additional components of
the mitochondrial contact site. This close association also suggests that PBR-VDAC may serve
as a target for modulating apoptosis and may have implications for drug design to treat such
disorders as cancer and neurodegenerative diseases [20].
4.2.4. Voltage-dependent anion channel (VDAC)
VDACs, also known as mitochondrial porins that show 68% similarity between mice and
humans. Among three VDAC isoforms, VDAC1 is the most widely expressed in mammals
followed by VDAC2 and then VDAC3. Studies have found that VDACs are highly conserved.
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Three isoforms of VDAC: VDAC1, VDAC2 and VDAC3 are reported. The additional exon in
VDAC2 is believed to encode part of the 5′-UTR region. VDAC1 and VDAC2 are expressed in
the skeletal muscles, heart, liver, and brain. There is also very low level expression of VDAC1
but only in the testes. VDAC3 is expressed in the spleen, lung, adrenal, ovary, liver, testicular
tissue and kidney muscles. Voltage dependent anion channel (VDAC) function functions in
the cell, including regulating mitochondrial shape and structural changes, regulating ATP
transport, regulating calcium transport, regulating apoptosis signaling, regulating hexokinase
interactions with mitochondria, regulating cell survival, growth, and fertility and maintaining
synaptic plasticity through mitochondrial permeability in the transition pore. These functions
have been found to be altered in cells from patients with mitochondrial and neurodegenerative
diseases, leading to mitochondrial dysfunction. As well as, increasing evidence suggests that
VDAC interacts with several cytoplasmic proteins, changes channel activity and VDAC
closure and reduces VDAC channel conductance. It is believed that VDAC is constantly open
in metabolic state. However, recent evidence suggests that VDAC closes intelligibly during
apoptosis in unhealthy neurons. As a result, with its pores closed, mitochondria may not be
able to uptake ADP, inorganic phosphate and respiratory substrates from the cytoplasm and
to release ATP into the cytoplasm. The pro-apoptotic protein tBid has been found to promote
the pore closure whereas anti-apoptotic proteinBcl2-XL has been found to prevent VDAC
closure. VDAC displays to be involved in both anti - and pro – apoptosis aspects of mitochon‐
dria. VDAC channel conductance may be impaired in a couple different ways. (1)Phosphory‐
lated VDAC may also interact with cytoplasmic proteins, leading to the blockade of
mitochondrial pores. Recently, in a study of brain tissue from postmortem brains of patients
with AD, Reddy and Manczak found that VDAC interacted with mutant AD proteins, which
in turn blocked mitochondrial pores and interrupted the flow of ADP, ATP, respiratory
substrates and inorganic phosphate substrates between mitochondria and the cytoplasm,
ultimately leading to mitochondrial dysfunction. (2) In neurons from mitochondrial diseases,
VDAC may interact with cytoskeletal and mutant proteins that may have accumulated during
disease progression and may have blocked the mitochondrial pores [25].
A lot of literature testes the role of VDAC in the regulation of cell death. VDAC is being studied
as a cancer-specific target because tumor cells have increased VDAC expression and glycolysis.
The role of VDAC1, VDAC2 and VDAC3, in cell death is intricate, but importantly, in vivo
evidence shows that in cancer cells, the association of VDAC1with HK prevents against
mitochondrial-mediated apoptosis. Therefore, disruption of the VDAC1-hexokinase (HK)
complex exhibits an attractive therapeutic cancer target. Over expression of HK1, 2 and their
connection with VDAC are notable characteristics of glycolytic cancer cells. It was found that
the VDACs expression has been elevated in cancerous cells compared with normal cells and
could be altered with chemotherapy. Increased VDAC concentration is an unfavorable
prognostic factor; moreover, RNA interference induced VDAC down regulation inhibits
cancer growth. This evidence seems in contrast with the finding that over expression of VDAC
induces apoptosis, but it illustrates how the context may influence the functional meaning of
a biological parameter. In cancer up regulation of VDAC goes hand in with HK2 up-regulation
and can be considered a component of glycolytic up-regulation. HK2 binding to VDAC, which
allows for ATP transport out of mitochondria, leads to a cancer cell metabolic advantage
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(termed the Warburg effect), and it antagonizes cell death through the inhibition of Bax-
induced cytochrome c release and/or inhibition of the MPT pore [26].
4.2.5. Changes in the configuration of MPT pore as a target in treatment
Cellular redox potential can be changed by function of OXPHOS proteins as well as by the
proliferative state. Elevations in intracellular oxidant potential can have discrete chemical
consequences: for example, a pair of cysteine thiols in the ANT becomes oxidized to a disulfide
linkage that results in opening of the MPT pore. Thus, manipulating cellular redox represents
an approach to altering mitochondrial function. Arsenic trioxide is currently marketed for the
treatment of acute promyelocytic leukemia. Its mechanism of action is undoubtedly multifac‐
torial but is understood to involve the formation of disulfide linkages in mitochondrial
proteins, including members of the MPT pore leading to their inhibition and the production
of ROS [27]. Elesclomol (STA-4783), an injectable drug currently undergoing Phase III clinical
evaluation for the treatment of metastatic melanoma, selectively kills cancer cells through
apoptosis as a result of an increase in their already raised oxidant level [28].
4.3. Superoxide dismutase (SOD) as a target in mitochondria
Superoxide dismutase (SOD) represents a group of enzymes that use as cofactor zinc and
copper, or nickel, iron, or manganese ions. There are three major families of superoxide
dismutase, depending on the metal cofactor: The Ni type, which binds nickel (only in prokar‐
yotes) and Cu/Zn (which binds both copper and zinc), Fe and Mn types (which bind either
iron or manganese). SOD1 is located in the cytoplasm, SOD2 in the mitochondria, and SOD3
is extracellular. The first is a dimer, whereas the others are tetramers (four subunits).SOD2,
the mitochondrial enzyme, has manganese in its reactive site whereas SOD1 and SOD3 contain
copper and zinc. [28]
A key role in oxidative stress protection is played by the manganese containing SOD2 in
mitochondria. This enzyme is also critical for fetus growth and viability n many eukaryotic
organisms, since complete loss of the enzyme results in neonatal lethality in mice. In addition
to oxidative tress nitrosative stress can completely inactivate mitochondrial Mn-SOD as well,
possibly through nitration of a single tyrosine residue (Tyr-34). Consequently, this favors
peroxynitrite generation in mitochondrion. Tyrosine nitration induced Mn-SOD inactivation
being identified in more than 50 human diseases including ischemia/reperfusion, inflamma‐
tion, human kidney allograft rejection and human pancreatic ductal adenocarcinoma [29].
The renal ischemia-reperfusion injury is one of the most important clinical xamples in which
Mn-SOD represents the main antioxidant protective mechanism. A significant increase in
superoxide production is  usually  associated with Ischemia/reperfusion conditions  which
leads to a rapid depletion of SOD. Therefore, any external therapeutic involvement needs
the sufficient amount of SOD to overcome the superoxide radical byproduct of ischemia-
reperfusion conditions. Any therapeutic administration of exogenous SOD fails due to short
half-life  of  the enzyme in plasma.  A way to ensure a  continuous production of  SOD is
entering  SOD  gene  in  renal  tissue  which  guarantees  protection  from  renal  ischemia-
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reperfusion injury. The effective gene delivery without toxic side effects was established by
intravenous injection of the gene vectors during experiments on animal models before the
ischemic insult. A significant progress in the area of kidney biology, especially in heredita‐
ry  kidney  disease  and  inflammatory  and  fibrotic  diseases  was  achieved  by  the  use  of
adenovirus as a vector for kidney-directed gene therapy [30]. Although some advantages
make adenoviral vectors suitable for gene transfer into complex organs such as the kidney.
But in contrast some disadvantages downgrade these vectors. For instance, the expression
of the transfected gene is limited to weeks or months in this technique, because adenovi‐
rus does not integrate into the host genome. Secondly, the adenovirus can elicit immunolog‐
ical  responses,  therefore  vector  cannot  be  administered  repeatedly.  During  emergency
situations in other inflammatory renal disease states, the SOD gene therapy with adenovi‐
ral vector is recommended, however, occurrence of harmful effects maximum within a week
is expected (e.g., post-transplant acute renal failure) [29].
ALS a neurodegenerative disease leads to paralysis, muscle wasting, and death, usually within
2 - 3 years of symptom onset due to death of motor neurons. The central mechanism by which
motor neuron death occurs in familial ALS is oxidative stress which is due to the mutations in
the antioxidant enzyme SOD1gene. Many hypotheses studied so far using ALS mouse models.
Some of these studies showed that SOD1 mutants have very low benefits (3, 35). One of the
most important pharmacological outcomes obtained in ALS mouse models was increasing
expression of either growth factors such glial cell-derived neurotrophic factor, IGF-1, and
VEGF (11–13) or RNAi molecules by the delivery of viral vectors (14–16) to silence SOD1
mutant gene expression. In gene therapy the primary cause of toxicity (i.e. mutant SOD1
proteins) is targeted, unlike drug therapy which usually acts on cell survival or deleterious
pathways [29].
Reduction of myocardial reperfusion injury through an effective immunization with SOD and
catalase has also been hypothesised. Indeed, the cardioprotective effect of intracoronary
infusion of SOD may further increase with coadministration of catalase. It is proven that
calcium antagonists, rennin-angiotensin system antagonists, Na+/H+ exchanger inhibitors,
nitric oxide donors and adenosine induce cardioprotective effects during primary angioplasty
for the management of acute myocardial infarction. When these reagents were administrated
using intracoronary infusion, their efficiency has increased. Another way to attenuate myo‐
cardial ischemia-reperfusion injury is anterograde intracoronary and intravenous adminis‐
tration of anti- P-selectin and anti- ICAM-1 antibodies. The ideal injection route for these
antibodies is retrograde intracoronary infusion, which has direct access to postcapillary
venules [29].
Application of inhibitors of cellular redox maintaining proteins which reduce intracellular ROS
is complementary to the use of pro-oxidant molecules, for example, administeration of catalase
or SOD in association with various peroxidases. 2-Methoxyestradiol by increasing cellular ROS
formation due to its inhibition of SOD, enhances the cytotoxic effects of apoptotic agents and
displays anti-leukemic activity in culture. On the other hand it has been hypothesized,
continuous mitochondrial ROS formation leading to oxidative stress and mitochondrial
damage has link to degenerative diseases and aging. Based on the ROS etiology of aging the
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ROS inhibition should have therapeutic benefit. Administration of antioxidants manganese
(III) tetrakis (4-benzoic acid) porphyrin (MnTBAP) or N-acetylcysteine also improved glucose
homoeostasis and insulin sensitivity in obese insulin-resistant mice [31]. MitoQ, a coenzyme
Q analog is currently in trial for the treatment of Parkinson’s Disease due to its potential
mitochondrial ROS inhibition. Knowing the beneficial effects of ROS shouldn’t underscore the
importance of a detailed knowledge of pathological conditions under which ROS formation
is happening, as well as the identity and biological half-life of the ROS produced.
Free radicals are generally involved in many pathological processes. The injuring mechanism
of reactive radical species is concentration dependent, which finally damages all cellular
constituents. Any insufficiency or functional failure in the body antioxidant systems results in
the shortening of the lifespan. Therefore, the first therapeutic approach is restoring the normal
function of the antioxidant enzymes like SOD.
4.4. Mitochondrial KATP channels target for therapy
Potassium channel openers (KCOs) are agents, discovered in the early 1980s, that act by
stimulating ion flux through K+ channels. Many drugs such as, diazoxide, nicorandil, and
cromakalim have been identified as KCOs. KCOs act on two types of ion channels: Ca2+
activated K+ channels (BK channels) and ATP-regulated K+ channels (KATP channels). KCOs
were first identified by their antihypertensive or antianginal mode of action. Now, they are at
various stages of development as and cardioprotective agents. Preclinical and clinical evidence
also supports the therapeutic role of KCOs in vascular and pulmonary hypertension, and the
treatment of overactive bladder. Until recently, it was believed that the effects of KCOs were
entirely attributed to the modulation of K+ channels in cell plasma membranes. However, it
is now proven, that new targets for KCOs exist in intracellular membranes including those of
mitochondria, zymogen granules, and sarcoplasmic reticulum. It seems that Mitochondria are
particularly very important targets for KCOs, because the interaction of these compounds with
mitochondria appears to mediate the cardioprotection of KCOs. The protective role of
mitochondrial ion channels was recently summarized and mitochondrial targets for anti-
ischemic drugs were recently described [32].
4.4.1. Potassium channel openers and mitochondrial K+ channels
A small-conductance potassium channel, with properties similar to those of the KATP channel
from the plasma membrane, in the inner membrane of rat heart and liver mitochondria and
designated the mitoKATP. The mitoKATP channel was blocked not only by ATP, but also,
similarly to the plasma membrane KATP channel, by antidiabetic sulfonylureas. These obser‐
vations raised the question whether the mitoKATP channel could be activated by KCOs. In fact,
an increased influx of K+ and depolarization of liver mitochondria in the presence of KCOs
was observed. Also, other KCOs were shown to activate potassium ion transport into mito‐
chondria. KCOs such as levcromakalim, cromakalim, and pinacidil have been shown to
depolarize cardiac mitochondria. KCO-induced membrane depolarization was associated
with an increase in the rate of mitochondrial respiration and decreased ATP synthesis.More‐
over, KCOs released cytochrome cand calcium ions from cardiac mitochondria. Despite the
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effect on K+ transport, diazoxide also exhibits a direct effect on mitochondrial energy metab‐
olism by inhibition of respiratory chain complex II in liver mitochondria. Recently, mitoKATP
channel opener BMS-191095 with no peripheral vasodilator activity was described.Using
isolated mitochondria or proteoliposomes reconstituted with partly purified mitoKATP channel
and measuring potassium flux demonstrated that heart and liver liver mitochondrial KATP
channels have some pharmacological similarities with the cell membrane KATP channel, i.e.,
both channels are activated by KCOs. Mitochondrial KATP channels are 1000 times more
sensitive to diazoxide than that of cell membrane KATP channels. This document concluded
that the interaction of mitochondrial KATP channels with KCOs plays a key role in cardiopro‐
tection [32].
4.4.2. Mitochondrial KATP channel: A novel target for cardioprotection
Mitochondrial KATP channel: A Novel target for Cardioprotection. KCOs mimic hypoxic/
ischemic preconditioning in the absence of ischemia in the heart myocardial cells, the reason
why antagonists of KATP channel, like 5-hydroxydecanoic acid and glibenclamide, ameliorate
the positive effects of short time hypoxic/ischemic conditions on the heart myocardium. The
primary postulation to justify these events includes cell membrane KATP channels. Newly, it
was shown that in fact KCOs including diazoxide affect the mitoKATP channel in mitochondria.
In a complementary approach, it was shown that diazoxide did not activate plasma membrane
KATP channels, but induced oxidation of mitochondrial flavoproteins, due to the activation of
mitoKATP channel. These findings established the fact that the target for the diazoxide protec‐
tive effects in heart myocytes is the mitochondrial KATP channel rather than the cell membrane
KATP channel. It is also note worthy that evidence for mitochondrial KATP channels as effectors
of cardiac myocardial preconditioning has also been proven in human subjects. The initial
observations on the cardioprotective action of KCOs on mitochondria were further confirmed
and developed in a series of reports. It has been shown that other KCOs such as nicorandil,
cromakalim, and pinacidil modulate mitochondrial Ca2+ uptake, respiration, mitochondrial
membrane potential, ATP generation, and mitochondrial Ca2+ uptake. The main question
remains how the opening of the mitoKATP channel could protect cells against ischemic damage.
1) Opening of the mitoKATP channel followed by mitochondrial swelling could improve
mitochondrial ATP handling and/or production. 2) The protective effect of mitoKATP activation
could be mediated by lowering Ca2+ overloading of mitochondria. In fact, it was found that
diazoxid preserves mitochondrial function in ischaemic rat cardiomyocyte. It is now proven
that hypoxia approximately decreases mitochondrial oxygen consumption rate to 40% of the
normal value, and administration of diazoxide maintains the prehypoxic mitochondrial
oxygen consumption rate during hypoxia/ischemia. Cardiac ATP concentration was signifi‐
cantly raised following diazoxide treatment. Secondly, by lowering Ca2+ overloading of
mitochondria the protective effect of mitochondrial KATP activation could be induced. It was
shown that the opening of the mitochondrial KATP channel may increase mitochondrial
reactive oxygen species (ROS) formation. This increase could lead to protein kinase C activa‐
tion, which is known to be necessary for the cardioprotection. Besides, it seems that mito‐
chondrial KATP channel is enrolled in delayed preconditioning because of an alteration in
expression of "protective" proteins (3). It was that pretreatment of hippocampal neurons with
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cromakalim and diazoxide increases the expression level of Bcl-2 and Bcl-XL which are
involved in the control of apoptosisBcl-2 [32].
5. Mitochondria as a biosensor for drug development
Extensive study over the last 50 years indicates that many medications can induce mitochon‐
drial damage [33]. Medication- induced dysfunctions include the alteration of mitochondrial
components and metabolic pathways. These dysfunctions are a major challenge and problem
for drug development. There is mounting evidence of the mitotoxicity (table 2).
Interestingly knowledge of the mechanisms that trigger drug-induced mitochondrial damage
will be helpful in the development of strategies to decrease the potentially toxic effects of
medications. Additional, these issues affect the most aerobically poised organs such as heart
and kidneys or organs exposed to higher concentrations of the drug for example liver. Recently
using mitochondria as a biosensor for determination safety of drug development has in‐
creased. The reasons are as follows: A) in general, mitochondria control many of the pro-death
and anti-death cell signals; B) a number of reports describe an association between patients
receiving medication and effects on mitochondrial metabolism 3) drug safety has become a
priority of many pharmaceutical companies [4].
It is quite obvious that mitochondria are key elements of cell life which several well known
drugs induce toxic effects on them in several non-target and target organs. As soon as possible
by improvement of preliminary drug safety assessment the possibility of drug toxic reactions
during clinical practice will be avoided. Depending on the targeted organ, severe in vitro
mitochondrial impairment may be sufficient to ban an efficient drug in the market or prevent‐
ing a promising drug candidate from further clinical trials. Drug companies now have a new
dilemma, which is to realize how much of the evaluated mitochondrial toxicity is a key
predictor of the drug pharmacological or adverse effects. Pharmaceutical suppliers have also
now a difficult problem which is to know how much of the supposedly mitochondrial
impairment is a component of the therapeutic effect. On the other hand, it may be a tough
choice to remove dispensing drugs showing a certain degree of mitochondrial toxicity in
vitro evaluations but with a very unique significant therapeutic effect. Despite showing
mitochondrial toxicity, sometimes pharmaceutical companies may decide to push the lead
candidate molecule forward for further in vivo assays in order to also clarify ways of reducing
adverse mitochondrial toxicity [3]. Some pharmacological strategies could be used to decrease
mitochondrial toxicity. For example in the cardiac toxicity of doxorubicin (DOX), One
possibility is to improve drug targeting, decreasing the amount of drug that reach non-target
organs. One successful example of this strategy is the use of pegylated liposomal DOX, which
has a quite different pharmacokinetic profile including an increased circulation time and a
decreased volume of distribution [34]. Another strategy is the co-administration of protective
agents, one example of which being the preventive role of the beta-blocker carvedilol on DOX
induced cardiac mitochondrial impairment.
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Hepatic Toxicity Renal Toxicity Cardiovascular Toxicity
- Metformin
- Valproic acid
- Ketoconazole
- Isoniazid
- Nefazodone
- Lamivudine
- Divalproex Sodium
- Tenofovir
- Didanosine
- Tamoxifen
- Nevirapine
- Zidovudine (AZT)
- Stavudine
- Flutamide
- Abacavir
- Phenoformin
- Zalcitabine
- Cysplatin
- Gentamicin
- Doxorubicin (DOX)
- Cyclosporin A
- Statins
- Ifosfamide
- Tenofovi
- Lidocaine
- Doxorubicin (DOX)
- Celecoxib
- Sorafenib
- Bupivacaine
- Diclofenac
- Daunorubicin
- Ibuprofen
- Piroxicam
- Thiazolidinediones
- Indomethacin
- Rosiglitazone
- Atenolol
-Nucleoside reverse transcriptase
inhibitors (NRTIs)
- Meloxicam
- Pioglitazone
- Sulindac
- Zidovudine (AZT)
- Idarubicin
- Piroxicam
- Mefenamic acid
- Daunorubicin
Table 2. Examples of Drugs with Black Box Warnings for Mitochondrial Toxicity
Refining of the different methodologies results into higher achievement in the isolation of
functional mitochondria from different organs, which can be used in further mechanistic
studies to identify tissue-specific drug-induced mitochondrial toxicity. Nevertheless, studies
with isolated mitochondria lack the complexity associated with experiments in intact cells,
isolated organs or even in vivo studies. But the use of isolated mitochondrial fractions helps
determining precise sites of action of the molecule on mitochondria. If everything works OK,
the accurate drug safety assessment would correlate data in isolated mitochondria with data
collected in intact cells and in vivo (figure 3).One important issue in this discussion includes
what can be gained by using mitochondria as a biosensor to search drug safety. One particular
example was nefazodone, an anti-depressant. This drug was withdrawn from the market in
2004, following several clinical reports of serious liver toxicity [35]. Would the use of mito‐
chondria as cost effective accelerated biosensors of drug safety helped in avoiding the entry
of the drug in the market? The answer is, maybe so. Dykenset al. demonstrated that nefazodone
is highly toxic to isolated liver mitochondria, human hepatocytes and HepG2 cells, showing
an obvious cytotoxicity even when cell lines were used. [36] If an initial assessment of
mitochondrial toxicity for nefazodone had been done, it is very unlikely that the drug would
have been pushed forward for further clinical trials.
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Figure 3. Basic scheme of the drug development process involving mitochondria  
as an important marker for drug-induced toxicity. The thickness of each arrow  
exemplifies the number of different molecules in each evaluation stage. Drug  
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Figure 3. Basic scheme of the drug development process involving mitochondria as an important marker for drug-in‐
duced toxicity. The thickness of each arrow exemplifies the number of different molecules in each evaluation stage.
Drug toxicity on mitochondria is proposed as the bottleneck step in decision-making [3].
It is now apparent that mitochondrial toxicology has become an area of interest to the industry,
since a primary assessment of mitochondrial toxicity of a range of compounds can be per‐
formed in a fast and relatively inexpensive way, avoiding some later human toxicity problems
that may arise during subsequent testing stages or even during clinical use. Some companies
will focus more on investigating direct drug-induced mitochondrial dysfunction, others will
rather measure drug-induced alterations in mitochondrial-relevant genes. Whatever the
chosen strategy is, the final outcome is the prediction of drug safety based on a mitochondrial
end-point.
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